Rhenman & Partners Asset Management Ab Krystal Biotech, Inc. Transaction History
Rhenman & Partners Asset Management Ab
- $1.2 Billion
- Q3 2024
A detailed history of Rhenman & Partners Asset Management Ab transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 17,000 shares of KRYS stock, worth $2.8 Million. This represents 0.26% of its overall portfolio holdings.
Number of Shares
17,000
Previous 19,000
10.53%
Holding current value
$2.8 Million
Previous $3.49 Million
11.41%
% of portfolio
0.26%
Previous 0.34%
Shares
2 transactions
Others Institutions Holding KRYS
# of Institutions
310Shares Held
24.3MCall Options Held
483KPut Options Held
364K-
Black Rock Inc. New York, NY3.95MShares$651 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.85MShares$470 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.62MShares$432 Million7.18% of portfolio
-
State Street Corp Boston, MA1.45MShares$239 Million0.01% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA988KShares$163 Million9.67% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $4.23B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...